Use of cystic fibrosis inhaled medication before and after elexacaftor/tezacaftor/ivacaftor initiation

Use of cystic fibrosis inhaled medication before and after elexacaftor/tezacaftor/ivacaftor initiation

•First multi-center study to investigate inhaled medication adherence post-ETI.•Medication adherence was calculated using the Medication Possession Ratio (MPR).•MPR for all inhaled medication was significantly decreased after ETI initiation. Elexacator/tezacaftor/ivacaftor (ETI) has improved cystic...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cystic fibrosis Vol. 23; no. 1; pp. 29 - 31
Main Authors: Manika, Katerina, Diamantea, Filia, Tsakona, Anna, Kakolyris, Alexandros, Sopiadou, Athina, Kotoulas, Serafeim-Chrysovalantis, Sionidou, Maria, Kirvasili, Sirmo-Stiliani, Hadji-Mitrova, Marija, Papadaki, Eleni, Chrysochoou, Elisavet-Anna, Hatziagorou, Elpis
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 01-01-2024
Subjects:
Adult
Aminophenols - adverse effects
Benzodioxoles - adverse effects
CFTR modulators
Cystic fibrosis
Cystic Fibrosis - diagnosis
Cystic Fibrosis - drug therapy
Cystic Fibrosis - genetics
Cystic Fibrosis Transmembrane Conductance Regulator - genetics
Humans
Indoles
Inhaled medications
Medication Possession Ratio
Multi-center study
Mutation
Prospective Studies
Pyrazoles
Pyridines
Pyrrolidines
Quinolones
Retrospective Studies
Use of treatment
FVC
CF
Inhaled medications
Medication Possession Ratio
CFTR modulators
Use of treatment
Multi-center study
Cystic fibrosis
FEV1
ETI
PwCF
MPR
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•First multi-center study to investigate inhaled medication adherence post-ETI.•Medication adherence was calculated using the Medication Possession Ratio (MPR).•MPR for all inhaled medication was significantly decreased after ETI initiation. Elexacator/tezacaftor/ivacaftor (ETI) has improved cystic fibrosis (CF) outcomes. A reduction in use of maintenance medication after its initiation has been reported. Seventy-one adult people with CF (PwCF) who are followed in three CF centers and completed one year of treatment with ETI were included in this study. Their use of inhaled dornase-α, colistin, tobramycin, aztreonam and levofloxacin during this period was compared with the corresponding use during one year without ETI, using the Medication Possession Ratio (MPR). MPR was significantly decreased after ETI initiation for dornase-α (67±35% vs 48±40%, p<0.001) and for all four inhaled antibiotics together (62±33% vs 41±37%, p<0.001). The findings of this multi-center, retrospective, study suggest that the initiation of ETI significantly leads to decrease in use of standard inhaled medication in PwCF. The significance of this finding in the course of the disease is yet to be investigated by larger prospective clinical trials.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1569-1993
1873-5010
DOI:10.1016/j.jcf.2023.05.001